Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy.

Maha S Al-KeilaniSamah AwadHanan M HammouriTala Al Shalakhti Basima A AlmomaniMuna M DahabrehMohammad-Jaafar Ajlony

Published in: PloS one (2023)

This study could only show significant changes in serum aCGRP levels following treatment of pulmonary exacerbations. Future studies with larger sample size are required to investigate the clinical importance of VIP and aCGRP in cystic fibrosis patients.

Keyphrases

cystic fibrosis
chronic obstructive pulmonary disease
pseudomonas aeruginosa
patients undergoing
pulmonary hypertension
end stage renal disease
lung function
newly diagnosed
ejection fraction
prognostic factors
bone marrow
patient reported outcomes
intensive care unit
combination therapy
case control